> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Alcon Defends $250 Million–$400 Million Retinal Treatment Forecast — Surgery Access Sets The Pace
- URL: https://www.bullished.co/alcon-defends-250-million-400-million-retinal-treatment-forecast-surgery-access-sets-the-d2da4752/
- Published: 2026-11-11T14:21:04.000Z
- Updated: 2026-11-11T14:21:04.000Z
- Description: Neurotech is expected to add 0.75–1 percentage point to companywide sales growth in 2027, with some near-term margin pressure.
- Author: Matteo Parrino
- Tags: Earnings, ALC, Industry: Healthcare

[Alcon](https://www.bullished.co/tag/alc/), which makes eye-care products for surgeons and consumers, expects $250 million–$400 million in peak sales from Neurotech's retinal treatment, Chief Executive Officer David Endicott said on the company's earnings call Wednesday. But he acknowledged that finding patients and getting them into surgery will determine how quickly the business grows.

## A Forecast With A Candid Caveat

A Wells Fargo analyst questioned whether the peak-sales estimate was too cautious given the potential patient pool. Endicott stood by the range while conceding: "you could be right and we could be wrong on this one".

Alcon counts approximately 25,000 diagnosed U.S. patients with macular telangiectasia, with another 2,000–3,000 diagnosed each year. The rare, progressive retinal disease can permanently damage central vision.

Neurotech's treatment uses encapsulated cells implanted surgically inside the eye. Endicott described it as the only FDA-approved treatment for the disease and said insurance coverage is largely established.

Coverage alone does not get patients treated. Endicott said the pace depends on locating these infrequently encountered patients, moving them through reimbursement and connecting them with centers prepared to perform the operation.

## Surgeons And Centers Govern Adoption

A Barclays analyst asked how much of the existing diagnosed population could benefit from treatment. Endicott described a slow-moving disease and emphasized the practical work of connecting patients with trained surgeons and willing surgical centers.

"The logistics of this, I think, are the piece that we're still working our way through," Endicott said. Unlike high-volume cataract operations, the procedure may occur only rarely at a given center, making it unfamiliar to many surgical facilities.

Alcon's Tuesday results release highlighted the recently [announced acquisition](https://www.sec.gov/Archives/edgar/data/0001167379/000116737926000033/q32026pressrelease.htm?ref=bullished.co). On Wednesday's call, Endicott said Alcon had bought Neurotech and that the treatment was already a year into launch.

The commercial plan centers on coordinating Neurotech's team with Alcon's existing retina sales force. Endicott expects to supplement the team with some resources, rather than build an entirely new sales operation.

The purchase fits Alcon's Surgical business, which supplies replacement lenses, instruments and equipment for eye procedures, including retinal surgery. Its Vision Care business sells contact lenses and products for conditions such as dry eye; Alcon generated $10.3 billion in sales in 2025.

## Growth Comes With Margin Pressure

Chief Financial Officer Tim Stonesifer clarified that Neurotech should add 0.75–1 percentage point to total Alcon sales growth in 2027\. The contribution applies across the company, rather than only to Vision Care.

The addition comes as Alcon expects its underlying eye-care markets to grow about 3% next year. Third-quarter sales [rose 5%](https://www.sec.gov/Archives/edgar/data/0001167379/000116737926000033/q32026pressrelease.htm?ref=bullished.co) to $2.7 billion, both as reported and excluding currency effects, compared with a year earlier.

Alcon narrowed its annual adjusted earnings-per-share growth outlook to 12%–14%. That represents a [one-percentage-point reduction](https://health.economictimes.indiatimes.com/news/medical-devices/alcon-shares-fall-as-tighter-eye-care-market-outlook-raises-growth-concerns/135736902?ref=bullished.co) in the upper end.

Stonesifer expects some near-term margin pressure from Neurotech, alongside higher costs for memory and resins. Alcon will also lap $60 million in tariff refunds and a $15 million milestone payment included in 2026 results, neither of which it expects to recur.

Management still expects margins to improve in 2027, helped by efficiency measures, but Stonesifer cautioned against treating the projected underlying cost leverage as the final margin gain.

Alcon plans to provide formal 2027 guidance in February, when investors will get more detail on the margin costs of bringing Neurotech's treatment to more patients.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [Alcon results release (Form 6-K, EX-99.1)](https://www.sec.gov/Archives/edgar/data/0001167379/000116737926000033/q32026pressrelease.htm?ref=bullished.co) — SEC EDGAR
- [Alcon Vision LLC (NYSE:ALC) : Articles :: Law360](https://www.law360.com/companies/alcon-vision-llc/articles?ref=bullished.co) — law360.com
- [Innovation and Product Launch Momentum Drive Alcon's Third-Quarter 2026 Growth – Company Announcement - FT.com](https://markets.ft.com/data/announce/detail?dockey=600-202611101630BIZWIRE%5FUSPRX%5F%5F%5F%5F20261108%5FBW755647-1&ref=bullished.co) — Financial Times
- [Alcon Stock Plummets 6% Amid Concerns Over Eye-Care Market Growth, ETHealthworld](https://health.economictimes.indiatimes.com/news/medical-devices/alcon-shares-fall-as-tighter-eye-care-market-outlook-raises-growth-concerns/135736902?ref=bullished.co) — health.economictimes.indiatimes.com
- [LENSAR, Inc. Q3 2026 Earnings Call Summary](https://finance.yahoo.com/markets/stocks/articles/lensar-inc-q3-2026-earnings-175740766.html?ref=bullished.co) — Yahoo Finance

### More on Alcon

- [Alcon Sales Rise 5% On Both Bases As It Narrows Its 2026 Outlook](https://www.bullished.co/alcon-sales-rise-5-on-both-bases-as-it-narrows-its-2026-outlook-ccc9c061/)

[All Alcon (ALC) coverage →](https://www.bullished.co/tag/alc/)